Wharton's jelly derived Mesenchymal stem cells. for respiratory distress syndrome

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trials ended early. Its trials were stopped early. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Jan 2020: Trial started, NCT04390152
  2. 15 May 2020: Trial registered, NCT04390152
  3. 3 Mar 2022: Trial terminated, NCT04390152

The trials

NCT04390152: Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19

State
Stopped early
Phase
Phase 1 and Phase 2
People
6 taking part
Started
13 Jan 2020
Primary completion
3 Mar 2022
Arms
Mesenchymal stem cell
Results
None posted
  1. 13 Jan 2020: Trial started
  2. 15 May 2020: Trial registered
  3. 3 Mar 2022: Trial terminated

How the status changed

  1. 19 Nov 2026: First set: Trials ended early

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.